MCAS Treatment: Medications, Supplements, and a Layered Approach to Mast Cell Stabilization

Why MCAS Treatment Requires a Layered Strategy

Mast cell activation syndrome is not a single-pathway disease. Mast cells release over 200 different mediators, including histamine, prostaglandins, leukotrienes, cytokines, heparin, and tryptase [1]. No single medication blocks all of these mediators. That is why MCAS treatment almost always involves multiple interventions layered on top of each other, each targeting a different arm of the mast cell response.

The standard approach most MCAS-experienced clinicians use is to start with the simplest, best-tolerated interventions and add layers based on symptom response. Rushing to complex regimens before establishing a baseline response to foundational therapies makes it difficult to know what is actually working.

Layer 1: H1 and H2 Antihistamines

Antihistamines are the first line of treatment for virtually every MCAS patient. They work by blocking histamine receptors, preventing the effects of one of the most abundant mediators mast cells release.

H1 Antihistamines

H1 receptors are found throughout the body and mediate symptoms like itching, hives, flushing, nasal congestion, and bronchoconstriction. H1 blockers commonly used in MCAS include:

• Cetirizine (Zyrtec): 10 to 20 mg daily, often divided into morning and evening doses. One of the most commonly used H1 blockers in MCAS due to documented mast cell-stabilizing properties beyond simple receptor blockade [2]
• Loratadine (Claritin): 10 mg once or twice daily. Well-tolerated, with minimal sedation
• Fexofenadine (Allegra): 180 mg once or twice daily. The least sedating option and often preferred in patients sensitive to drowsiness
• Hydroxyzine: 10 to 50 mg, typically at bedtime due to sedating effects. Can be helpful for patients with MCAS-related insomnia and anxiety

Many MCAS patients require higher-than-standard doses of H1 blockers. It is common for clinicians to prescribe double or even quadruple the over-the-counter dosing, though this should be done under medical supervision [3].

H2 Antihistamines

H2 receptors are concentrated in the gastrointestinal tract, and H2 blockers address GI symptoms like reflux, nausea, abdominal pain, and diarrhea that antihistamines alone may not resolve. Common options include:

• Famotidine (Pepcid): 20 to 40 mg twice daily. The most widely used H2 blocker in MCAS practice
• Ranitidine: Previously popular but removed from the market due to NDMA contamination concerns

The combination of an H1 and H2 blocker together is significantly more effective than either alone [4]. Most MCAS clinicians consider dual antihistamine therapy the minimum starting point for treatment.

Practical Notes on Antihistamines

Some MCAS patients react to the inactive ingredients (fillers, dyes, preservatives) in antihistamine tablets rather than the active drug itself. If you seem to react to a medication that should be helping, try a different brand or formulation. Dye-free versions, liquid formulations, or compounded preparations without common excipients can make the difference between tolerating and not tolerating a medication [5].

Layer 2: Mast Cell Stabilizers

While antihistamines block the effects of histamine after it has been released, mast cell stabilizers work upstream by preventing the degranulation event itself. For many patients, this is where treatment goes from “somewhat helpful” to “life-changing.”

Cromolyn Sodium (Gastrocrom)

Cromolyn sodium is the most established mast cell stabilizer for gastrointestinal MCAS symptoms. It works locally in the gut by stabilizing mucosal mast cells and preventing mediator release [6].

• Typical dosing: 100 to 200 mg (1 to 2 ampules) four times daily, taken 15 to 20 minutes before meals and at bedtime
• Onset: Response may take 2 to 6 weeks. Some patients do not see full benefit until 8 to 12 weeks
• Key advantage: Extremely low systemic absorption (less than 1% is absorbed from the GI tract), making it one of the safest medications available
• Common issue: The liquid ampule formulation tastes unpleasant. Mixing it with a small amount of water or using the nebulizer formulation orally can help

Cromolyn is particularly effective for patients whose primary symptoms are GI-related: nausea, cramping, diarrhea, and abdominal pain after eating.

Ketotifen

Ketotifen is a dual-action agent that functions as both a mast cell stabilizer and an H1 antihistamine. It is available by prescription in many countries but is not FDA-approved in the United States for oral use, which means American patients typically obtain it through compounding pharmacies [7].

• Typical dosing: 0.5 to 2 mg twice daily. Start low (0.5 mg at bedtime) due to initial sedation
• Sedation: Drowsiness is common in the first 1 to 2 weeks but usually resolves as the body adjusts
• Benefits: Effective for both GI and systemic MCAS symptoms. Many patients report improvement in brain fog, flushing, and GI distress

Ketotifen is often considered one of the more effective single agents for MCAS because of its dual mechanism. Patients who have partially responded to separate H1 blockers and cromolyn sometimes find that ketotifen alone covers what two medications previously managed [8].

Layer 3: Leukotriene Inhibitors

Mast cells release leukotrienes, which are potent inflammatory mediators that contribute to bronchoconstriction, mucus production, and vascular permeability. Leukotriene pathway inhibitors can address symptoms that antihistamines and mast cell stabilizers miss.

• Montelukast (Singulair): 10 mg once daily. Originally developed for asthma, it addresses respiratory symptoms, nasal congestion, and some systemic inflammatory symptoms in MCAS patients [9]
• Zileuton (Zyflo): 600 mg four times daily (or 1200 mg twice daily for extended-release). Works upstream of montelukast by inhibiting the 5-lipoxygenase enzyme. Requires liver function monitoring but can be effective for patients who do not respond to montelukast

A note on montelukast: the FDA added a black box warning regarding potential neuropsychiatric side effects (mood changes, agitation, suicidality). While these side effects appear to be uncommon, MCAS patients and providers should monitor for mood changes, particularly in the first few weeks [10].

Layer 4: Dietary Intervention

The Low-Histamine Diet

Diet is not a replacement for medication in moderate-to-severe MCAS, but it is a powerful adjunct. A low-histamine diet reduces the total histamine load entering the body from food, giving your already-overburdened mast cells less to react to.

High-histamine foods to reduce or avoid include:

• Aged cheeses, cured and smoked meats, fermented foods (sauerkraut, kimchi, kombucha)
• Alcohol (especially red wine and beer)
• Canned or leftover fish and meats
• Vinegar, soy sauce, fish sauce
• Tomatoes, spinach, eggplant, avocado
• Citrus fruits, strawberries, dried fruits
• Chocolate, cocoa

The freshness of food matters as much as the food itself. Histamine accumulates as food ages, so eating freshly prepared meals and freezing leftovers immediately (rather than refrigerating for days) can significantly reduce histamine exposure [11].

Most patients can assess whether the low-histamine diet is helping within 2 to 4 weeks of strict adherence. Once symptoms stabilize, individual foods can be reintroduced one at a time to identify personal triggers.

Layer 5: Targeted Supplements

Quercetin

Quercetin is a plant flavonoid with documented mast cell-stabilizing and anti-inflammatory properties. In vitro studies show it inhibits histamine release from mast cells and reduces the production of pro-inflammatory cytokines [12]. Typical dosing in MCAS is 500 to 1000 mg two to three times daily, taken with meals. Quercetin has poor bioavailability on its own; formulations combined with bromelain or in phytosome form (quercetin bound to phospholipids) are better absorbed.

Vitamin C

Vitamin C supports the enzymatic breakdown of histamine by the diamine oxidase (DAO) enzyme and has been shown to reduce blood histamine levels at doses of 1000 to 2000 mg daily [13]. It also has antioxidant properties that may help manage oxidative stress associated with mast cell activation. Buffered or liposomal forms are generally better tolerated, as high-dose ascorbic acid can cause GI upset in sensitive patients.

DAO Supplements

Diamine oxidase is the primary enzyme responsible for breaking down ingested histamine in the gut. Some MCAS patients have reduced DAO activity, whether due to genetic variants, gut inflammation, or medications that inhibit DAO function. Supplemental DAO (typically derived from porcine kidney) taken before meals can help break down histamine from food before it is absorbed [14].

DAO supplements do not affect endogenous histamine (histamine produced inside the body by mast cells). They only address dietary histamine. For this reason, DAO is most useful as a dietary adjunct rather than a standalone treatment.

Other Supplements Worth Considering

• Luteolin: Another flavonoid with mast cell-stabilizing properties, sometimes combined with quercetin
• N-acetylcysteine (NAC): 600 to 1200 mg daily. Supports glutathione production and may reduce mast cell activation
• Magnesium: Deficiency is common in MCAS patients and may worsen mast cell reactivity. Glycinate or threonate forms are generally well-tolerated

Trigger Avoidance

No medication regimen will work well if you are constantly exposed to triggers that are activating your mast cells. Common MCAS triggers include:

• Temperature extremes (heat is a particularly common trigger)
• Emotional stress and physical overexertion
• Fragrances, perfumes, cleaning chemicals, and volatile organic compounds
• Certain medications (NSAIDs, opioids, some antibiotics, contrast dyes)
• Insect stings and venom
• Hormonal fluctuations (many women report symptom flares around menstruation)
• Mold exposure

Keeping a symptom and trigger diary for the first few months of treatment can reveal patterns that are not obvious without systematic tracking. Many patients discover that their “random” flares actually follow identifiable environmental or behavioral triggers [15].

Advanced Therapy: Omalizumab (Xolair)

For patients with refractory MCAS who have not responded adequately to the layered approach above, omalizumab (Xolair) is an option. Omalizumab is a monoclonal antibody that binds IgE and reduces mast cell surface IgE receptor expression, effectively lowering mast cell reactivity [16].

Originally approved for severe allergic asthma and chronic urticaria, omalizumab has shown benefit in MCAS patients in case series and small studies. It is administered as a subcutaneous injection every 2 to 4 weeks and requires preauthorization from insurance in most cases. Response can take 3 to 6 months to become apparent.

Cost is significant (often over $1,000 per injection without insurance), and not all MCAS patients respond. But for those who do, the improvement can be substantial.

How to Layer Treatment: A Practical Sequence

While every patient is different, the general sequencing most MCAS-experienced clinicians follow looks something like this:

1. Start with an H1 antihistamine and an H2 antihistamine together
2. Add a low-histamine diet
3. Introduce quercetin and vitamin C as tolerated
4. Add a mast cell stabilizer (cromolyn or ketotifen) if antihistamines alone are insufficient
5. Consider a leukotriene inhibitor for persistent respiratory or inflammatory symptoms
6. Add DAO enzymes before meals if dietary histamine remains problematic
7. Reserve omalizumab for cases that remain refractory after optimizing all of the above

Each new intervention should be added one at a time with at least 2 to 4 weeks between additions. This allows you and your clinician to identify what is helping and what is causing problems. MCAS patients are often sensitive to new inputs, so starting medications at lower-than-standard doses and titrating up slowly is standard practice.

Related Reading

• Mast Cell Activation Syndrome: Complete Guide
• MCAS Diagnosis: Criteria, Testing, and Why It Gets Missed
• Low-Histamine Diet for MCAS: What to Eat and Avoid
• Histamine Intolerance: Causes, Symptoms, and Management

References

1. Theoharides TC, Valent P, Akin C. “Mast Cells, Mastocytosis, and Related Disorders.” N Engl J Med. 2015;373(2):163-172. doi:10.1056/NEJMra1409760
2. Cereza G, Garcia Dolade N, Laporte JR. “Cetirizine-induced mast cell stabilization: review of in vitro and clinical evidence.” Allergy. 2000;55(3):203-209.
3. Molderings GJ, Brettner S, Homann J, Afrin LB. “Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.” J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10
4. Lin RY, Curry A, Pesola GR, et al. “Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists.” Ann Emerg Med. 2000;36(5):462-468. doi:10.1067/mem.2000.109445
5. Afrin LB, Self S, Menk J, Lazarchick J. “Characterization of Mast Cell Activation Syndrome.” Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.2016.12.013
6. Horan RF, Sheffer AL, Austen KF. “Cromolyn sodium in the management of systemic mastocytosis.” J Allergy Clin Immunol. 1990;85(5):852-855. doi:10.1016/0091-6749(90)90067-E
7. Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. “A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis.” J Allergy Clin Immunol. 1989;83(5):866-870. doi:10.1016/0091-6749(89)90098-0
8. Escribano L, Akin C, Castells M, et al. “Mastocytosis: current concepts in diagnosis and treatment.” Ann Hematol. 2002;81(12):677-690. doi:10.1007/s00277-002-0575-z
9. Tolar J, Tope WD, Neglia JP. “Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.” N Engl J Med. 2004;350(7):735-736. doi:10.1056/NEJM200402123500723
10. US Food and Drug Administration. “FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair).” FDA Drug Safety Communication. March 2020.
11. Maintz L, Novak N. “Histamine and histamine intolerance.” Am J Clin Nutr. 2007;85(5):1185-1196. doi:10.1093/ajcn/85.5.1185
12. Weng Z, Zhang B, Asadi S, et al. “Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans.” PLoS One. 2012;7(3):e33805. doi:10.1371/journal.pone.0033805
13. Johnston CS, Martin LJ, Cai X. “Antihistamine effect of supplemental ascorbic acid and neutrophil chemotaxis.” J Am Coll Nutr. 1992;11(2):172-176.
14. Manzotti G, Breda D, Di Gioacchino M, Burastero SE. “Serum diamine oxidase activity in patients with histamine intolerance.” Int J Immunopathol Pharmacol. 2016;29(1):105-111. doi:10.1177/0394632015617170
15. Afrin LB. “Mast cell activation disease and the modern epidemic of chronic inflammatory disease.” Transl Res. 2016;174:33-59. doi:10.1016/j.trsl.2016.01.003
16. Molderings GJ, Raithel M, Kratz F, et al. “Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.” Intern Med. 2011;50(6):611-615. doi:10.2169/internalmedicine.50.4640